目的 探討鼻淵舒口服液聯(lián)合頭孢克肟治療慢性鼻竇炎的臨床療效。方法 選取2021年5月—2022年4月長(zhǎng)江航運(yùn)總醫(yī)院收治的168例慢性鼻竇炎患者，按隨機(jī)數(shù)字表法將所有患者分為對(duì)照組和治療組，每組各84例。對(duì)照組口服頭孢克肟膠囊，100 mg/次，2次/d。治療組在對(duì)照組基礎(chǔ)上口服鼻淵舒口服液，10 mL/次，3次/d。兩組均連續(xù)治療2周。觀察兩組臨床療效，比較治療前后兩組患者相關(guān)量表[鼻腔鼻竇結(jié)局測(cè)試-20（SNOT-20）評(píng)分、主觀病情視覺(jué)模擬量表（VAS）評(píng)分、Lund-Mackay評(píng)分、Lund-Kennedy評(píng)分、36項(xiàng)健康調(diào)查簡(jiǎn)表（SF-36）]及血清腫瘤壞死因子-α（TNF）-α、白細(xì)胞介素-12（IL-12）、超敏C反應(yīng)蛋白（hs-CRP）、轉(zhuǎn)化生長(zhǎng)因子-β1（TGF-β1）水平。結(jié)果 治療后，治療組總有效率是95.24%，顯著高于對(duì)照組的85.71%（P＜0.05）。治療后，兩組SNOT-20中鼻部癥狀評(píng)分、睡眠障礙評(píng)分、相關(guān)癥狀評(píng)分、情感結(jié)局評(píng)分和總分均較治療前顯著降低（P＜0.05）；且均以治療組下降更顯著（P＜0.05）。治療后，兩組主觀病情VAS評(píng)分、Lund-Mackay評(píng)分、Lund-Kennedy評(píng)分均顯著下降，SF-36總分均顯著增加（P＜0.05）；且均以治療組改善更顯著（P＜0.05）。治療后，兩組血清TNF-α、IL-12、hs-CRP、TGF-β1水平較治療前均顯著下降（P＜0.05）；且均以治療組降低更顯著（P＜0.05）。結(jié)論 鼻淵舒口服液聯(lián)合頭孢克肟治療慢性鼻竇炎的整體療效確切，能明顯緩解患者癥狀，減輕病情嚴(yán)重程度，提高生活質(zhì)量，并能有效下調(diào)血清TNF-α、IL-12、hs-CRP、TGF-β1水平，且安全性好。

Objective To investigate the clinical efficacy of Biyuanshu Oral Liquid combined with cefixime in treatment of chronic sinusitis. Methods A total of 168 patients with chronic sinusitis admitted to General Hospital of The Yangtze River Shipping from May 2021 to April 2022 were selected and divided into control group and treatment group according to random number table method, with 84 cases in each group. Patients in the control group were po administered with Cefixime Capsules, 100 mg/time, twice daily. Patients in the treatment group po administered with Biyuanshu Oral Liquid on the basis of the control group, 10 mL/time, 3 times daily. Both groups were treated continuously for 2 weeks. The clinical curative effects of the two groups were observed, and the related scales [Nasal and Sinus Outcome Test-20 (SNOT-20), Visual Analogue Scale (VAS), Lund-Mackay, Lund-Kennedy, 36-item Health Survey Short Form (SF-36)] score and serum tumor necrosis factor (TNF)-α, interleukin (IL)-12, high-sensitivity C-reactive protein (hs-CRP), transforming growth factor beta 1 (TGF) -β1) level before and after the treatment were compared. Results After treatment, the total effective rate of the treatment group was 95.24%, which was significantly higher than that of the control group (85.71%, P < 0.05). After treatment, nasal symptom score, sleep disorder score, related symptom score, emotional outcome score and total score of SNOT-20 in two groups were significantly decreased compared with before treatment (P < 0.05). The decrease was more significant in treatment group (P < 0.05). After treatment, the subjective VAS score, Lund-Mackay score, and Lund-Kennedy score were significantly decreased, and the total score of SF-36 was significantly increased in both groups (P < 0.05). The improvement was more significant in treatment group (P < 0.05). After treatment, serum levels of TNF-α, IL-12, hs-CRP, and TGF-β1 in two groups were significantly decreased compared with before treatment (P < 0.05). The decrease was more significant in treatment group (P < 0.05). Conclusion Biyuanshu Oral Liquid combined with cefixime has a definite overall curative effect in treatment of chronic sinusitis, and can significantly relieve the symptoms of patients, reduce the severity of the disease, improve the quality of life, and can effectively down-regulate serum TNF-α, IL-12, hs-CRP, the expression level of TGF-β1, and the safety is good.

R987

武漢市衛(wèi)生健康科研基金資助項(xiàng)目（WX19D58）